Board of Directors
Edward J. Fiorentino
Chairman and Chief Executive Officer
Ed Fiorentino is Chairman of the Board and CEO of TerSera Therapeutics. Previously, Ed was Chairman of the Board and CEO of specialty pharmaceutical company Crealta Pharmaceuticals, and CEO of Actient Pharmaceuticals.
Prior to Crealta and Actient, Ed was with Abbott for more than 20 years. His senior-level management experience at Abbott includes Corporate Vice President of pharmaceutical commercial operations; Senior Vice President and President of Abbott Diabetes Care; and Executive Vice President of TAP Pharmaceuticals, an Abbott joint venture with Takeda Pharmaceuticals. Ed began his career with Bristol-Myers.
Ed currently serves on the boards of TerSera Therapeutics, Senseonics and Clearbrook. He previously served on the boards of Crealta Pharmaceuticals, Actient Pharmaceuticals, TAP Pharmaceuticals, Graceway Pharmaceuticals, iBIO, California Healthcare Institute, National Pharmaceutical Council and Allendale Association. Ed holds a B.S. in Business Administration from the State University of New York and an M.B.A. from Syracuse University.
Joseph S. Bailes M.D.
Past President, American Society of Clinical Oncology (ASCO)
Dr. Bailes is a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy. For nearly two decades, he served in various executive leadership capacities for the American Society of Clinical Oncology (ASCO), including terms as President, Interim Executive Vice President and Chief Executive Officer, and Chair of the ASCO Government Relations Council.
Dr. Bailes has many years of experience in the practice of oncology in the private sector as a former partner in Texas Oncology, P.A., the largest oncology practice group in the country, and as a founding member of Physician Reliance Network (PRN), one of the corporate predecessors to US Oncology, Inc. Dr. Bailes served as President of PRN Research, where he oversaw clinical trials and drug development activities. Subsequently, he was Executive Vice President for Clinical Affairs with US Oncology. He served on the Board of Directors of Ilex Oncology.
Dr. Bailes received his medical degree from the University of Texas Southwestern Medical School at Dallas, followed by his internship and residency at Parkland Memorial Hospital in Dallas. He completed his Medical Oncology/Hematology Fellowship at the University of Texas Health Science Center in San Antonio. In addition to his private practice experience, Dr. Bailes has served as Clinical Assistant Professor at the University of Texas Health Science Center.
Mark T. Brandt, M.D., F.A.C.S.
Chairman, Division of Urology, Advocate Lutheran General Hospital
Dr. Brandt is the current Chairman of the Division of Urology at Advocate Lutheran General Hospital in Park Ridge and the former Chairman of Urology at Presence Resurrection Medical Center in Northwest Chicago. He maintains a very active surgical and clinical practice within Uropartners, one of the largest Urology groups in the country, where he also serves on its board of directors. He also previously served on the board of Actient Pharmaceuticals.
Dr. Brandt has a broad clinical practice including urologic cancer, stone disease, female urology and prostate problems/men's health. He is a leader in minimally invasive and robotic surgery for prostate cancer, kidney tumors and adrenal problems. He has performed hundreds of advanced robotic and laparoscopic surgeries and led the team performing the first laparoscopic radical nephrectomy at Advocate Lutheran General Hospital over 15 years ago.
Dr. Brandt is a graduate of University of Michigan Medical School and completed general surgery training in Boston and Urology residency at The University of Cincinnati. He is a clinical professor with teaching duties for both residents and students who benefit from his wide range of interests. In addition to his clinical and administrative achievements, he is a long-term member of several professional societies including the Board of Urology, the Society of Laparoendoscopic Surgery, and is a Fellow of the American College of Surgery.
Benjamin J. Daverman
Managing Director, GTCR
Ben joined GTCR in 2008. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in history magna cum laude from Colgate University. Ben also holds a master’s degree in biotechnology from the School of Applied Sciences & Engineering at the University of Pennsylvania.
Ben is currently a Director of TerSera Therapeutics, Maravai LifeSciences and XIFIN. He was previously on the boards of Actient Pharmaceuticals, Cole-Parmer, Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics.
John C. Landgraf
Retired Abbott Executive
John Landgraf was the executive vice president, Abbott Nutritional Products, Abbott’s largest business.
John was with Abbott for 38 years. His other senior-level management experience at Abbott includes Senior Vice President, Global Pharmaceutical Manufacturing and Supply; Vice President, Quality Assurance and Compliance, for Abbott's Medical Products Group; Vice President of Abbott’s Global Engineering Services; and various other management positions in manufacturing and engineering with Abbott International and Abbott Diagnostics. John began his career at Inolex Corporation in Glenwood, Ill.
John serves on the boards of TerSera Therapeutics, University of Illinois IGB External Advisory Board, the Boy Scouts of America Northeast Illinois Council, the National STEM Advisory Board for the Boy Scouts of America and the Mailisita Foundation and Education Center. He previously served on the board of Crealta Pharmaceuticals.
John earned a bachelor's degree in biology and a master's degree in microbiology from Northern Illinois University and a master's degree in business administration from the Lake Forest Graduate School of Management.
Dean S. Mihas
Managing Director, GTCR
Dean joined GTCR in 2001. Prior to joining GTCR, Dean was CEO and co-founder of Delray Farms, LLC, a specialty food retailer. Prior to Delray Farms, Dean was with McKinsey & Company. Dean holds an MBA with distinction from the Harvard Business School and a BS with high distinction in finance and economics from the University of Illinois, Chicago.
Dean is head of the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices. He is currently a Director of TerSera Therapeutics, Cedar Gate Technologies, Maravai LifeSciences, Riverchase Dermatology, Rx30, Sterigenics, and XIFIN. He was previously on the boards of Actient Pharmaceuticals, ATI Physical Therapy, Cole-Parmer, Cord Blood Registry, Crealta Pharmaceuticals, Curo Health Services, Devicor Medical Products, Ovation Pharmaceuticals, Managed Healthcare Associates and Polypore.